![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
On the first day after surgery, patients receiving ORAVEXX (cannabidiol, CBD), experienced on average 23% less pain as measured by the Visual Analog Scale (VAS) pain score compared to patients receiving the placebo.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Oravexx
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NYU Langone Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022